American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer☆

Gaspar, Laurie E.; Nag, Subir; Herskovic, Arnold; Mantravadi, Rao V.P.; Speiser, Burton L.

doi:10.1016/s0360-3016(97)00231-9

Cited by 141 publications

(52 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…New surgical procedures and endoscopic treatments of early tumors have been developed (7) as has the use of intraluminal brachytherapy (8). However, with early dissemination, it seems rational to use systemic treatment modalities such as chemotherapy and not just the locoregional techniques of surgery and:or radiation.…”

Section: Original Articlementioning

confidence: 99%

A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus

et al. 2001

View full text Add to dashboard Cite

Section: Original Articlementioning

confidence: 99%

A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus

et al. 2001

View full text Add to dashboard Cite

“…10 Harvey et al reported mean dysphagia relief duration of 4.5 months and survival of 5.8 months in their experience with HDR brachytherapy. 11 Ghosh S et al reported significant improvement in swallowing status in 20 patients (57.14%) since just after treatment and up to 7.5 months.…”

Section: 6mentioning

confidence: 97%

Palliation of advanced/metastatic carcinoma esophagus with radiotherapy

2015

View full text Add to dashboard Cite

“…The treatment resulted in favorable local control and long-term survival rates with tolerable side efects [29]. Patient selection, timing of brachytherapy and dose speciications were well documented [30][31][32]. Clinicians continue to urge caution in using brachytherapy treatment techniques since severe toxicity can occur post treatment [15,26,30].…”

Section: Brachytherapy Of Esophageal Cancermentioning

confidence: 99%

“…Patient selection, timing of brachytherapy and dose speciications were well documented [30][31][32]. Clinicians continue to urge caution in using brachytherapy treatment techniques since severe toxicity can occur post treatment [15,26,30]. Therefore, the addition of brachytherapy, with consequently high surface doses, should be limited to wellselected patients [33].…”

Section: Brachytherapy Of Esophageal Cancermentioning

confidence: 99%

Radiation Therapy for Esophageal Cancer

Buzurović¹,

Daróczi²,

O’Farrell³

et al. 2017

Esophageal Abnormalities

View full text Add to dashboard Cite

Esophageal cancer develops in the mucosa of the esophagus and spreads toward the muscle layer. The nonsurgical treatment for localized, deeply invasive esophageal cancer has been external beam radiation therapy (EBRT) and concurrent chemotherapy. Recently, intraluminal brachytherapy showed a strong potential for the improvement of the therapeutic ratio. It was found that the fractionated high dose rate (HDR) brachytherapy ofered beneicial palliation for a longer period of time with more durable symptom control. A similar was concluded for advanced unresectable esophageal cancer in previously irradiated patients. HDR brachytherapy may be a useful salvage treatment option for inoperable patients diagnosed with local esophageal cancer. Although beter local control can be achieved with higher brachytherapy dose, this increases the risk of acute morbidity and late morbidity, especially in the seting of recurrence cancer. It was found that the moderate dose of EBRT and HDR brachytherapy could give a beter local response than EBRT alone.

show abstract

American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer☆

Cited by 141 publications

References 17 publications

A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus

A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus

Palliation of advanced/metastatic carcinoma esophagus with radiotherapy

Radiation Therapy for Esophageal Cancer

Contact Info

Product

Resources

About